Immune cells: more than simple carriers for systemic delivery of oncolytic viruses

Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in whi...

Full description

Bibliographic Details
Main Authors: Eisenstein, Samuel, Chen, Shu-Hsia, Pan, Ping-Ying
Format: Online
Language:English
Published: Dove Medical Press 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354653/
id pubmed-4354653
recordtype oai_dc
spelling pubmed-43546532015-03-10 Immune cells: more than simple carriers for systemic delivery of oncolytic viruses Eisenstein, Samuel Chen, Shu-Hsia Pan, Ping-Ying Review Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses. Dove Medical Press 2014-11-06 /pmc/articles/PMC4354653/ /pubmed/25767789 http://dx.doi.org/10.2147/OV.S47143 Text en © 2014 Eisenstein et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Eisenstein, Samuel
Chen, Shu-Hsia
Pan, Ping-Ying
spellingShingle Eisenstein, Samuel
Chen, Shu-Hsia
Pan, Ping-Ying
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
author_facet Eisenstein, Samuel
Chen, Shu-Hsia
Pan, Ping-Ying
author_sort Eisenstein, Samuel
title Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
title_short Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
title_full Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
title_fullStr Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
title_full_unstemmed Immune cells: more than simple carriers for systemic delivery of oncolytic viruses
title_sort immune cells: more than simple carriers for systemic delivery of oncolytic viruses
description Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses.
publisher Dove Medical Press
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354653/
_version_ 1613197000285618176